Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises the Private Equity-fund SSVP on acquisition of EuroMaint
Mandate

Vinge advises the Private Equity-fund SSVP on acquisition of EuroMaint

October 26, 2016

Vinge is advising SSVP, a fund advised by Private Equity advisor Orlando Nordics, in connection with the acquisition of all the shares in EuroMaint Gruppen AB (“EuroMaint”) from Ratos AB (publ.).

EuroMaint is a leading independent maintenance provider for the Swedish rail transport industry, and has a network of workshops from Luleå in the north to Malmö in the south of Sweden. EuroMaint head office is located in Solna, Sweden and the company has approximately 1050 employees. The transaction is conditional upon approval from competition authorities.

Vinge’s team includes, inter alia, Magnus Hedsund, Anna Edström, Kristoffer Franzkeit, Jessica Salomonsson (M&A), Mathias Lindquist (environmental law), Maria Schultzberg (tax) and Fabian Ekeblad, Adam Sandberg and Josefine Lanker (financing).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025